Cargando…

Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways

Elotuzumab is a humanized monoclonal antibody specific for signaling lymphocytic activation molecule-F7 (SLAMF7, also known as CS1, CD319, or CRACC) that enhances natural killer (NK) cell-mediated antibody-dependent cellular cytotoxicity (ADCC) of SLAMF7-expressing myeloma cells. This study explored...

Descripción completa

Detalles Bibliográficos
Autores principales:	Balasa, Balaji, Yun, Rui, Belmar, Nicole A., Fox, Melvin, Chao, Debra T., Robbins, Michael D., Starling, Gary C., Rice, Audie G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4282702/ https://www.ncbi.nlm.nih.gov/pubmed/25287778 http://dx.doi.org/10.1007/s00262-014-1610-3

Ejemplares similares

Elotuzumab for multiple myeloma
Publicado: (2022)

The efficacy of combination treatment with elotuzumab and lenalidomide is dependent on crosstalk between natural killer cells, monocytes and myeloma cells
por: Richardson, Kelden, et al.
Publicado: (2022)

Elotuzumab for the treatment of multiple myeloma
por: Wang, Yucai, et al.
Publicado: (2016)

Profile of elotuzumab and its potential in the treatment of multiple myeloma
por: Liu, Yi-Chang, et al.
Publicado: (2014)

Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date
por: Weisel, Katja
Publicado: (2016)

Elotuzumab: The First Monoclonal Antibody for the Treatment of Multiple Myeloma
por: Fancher,(1,2), Karen M., et al.
Publicado: (2016)

Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study
por: Jagannath, Sundar, et al.
Publicado: (2018)

Downregulation of Chemokine CCL20 Involved in Myeloma Cells Resistant to Elotuzumab and Lenalidomide
por: Wang, Huihan, et al.
Publicado: (2021)

Treatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumab
por: Einsele, Hermann, et al.
Publicado: (2016)

Emerging combination therapies for the management of multiple myeloma: the role of elotuzumab
por: Chen, Wei-Chih, et al.
Publicado: (2017)

Clinical potential of SLAMF7 antibodies – focus on elotuzumab in multiple myeloma
por: Friend, Reed, et al.
Publicado: (2017)

Elotuzumab spares dendritic cell integrity and functionality
por: Schlaweck, Sebastian, et al.
Publicado: (2021)

Update on elotuzumab for the treatment of relapsed/refractory multiple myeloma: patients’ selection and perspective
por: Trudel, Sabrina, et al.
Publicado: (2019)

Overcoming Proteasome Inhibitor-Refractory Multiple Myeloma With Elotuzumab, Bortezomib, Nelfinavir, and Dexamethasone
por: Erath, Alexandra, et al.
Publicado: (2020)

Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma
por: Campbell, Kerry S., et al.
Publicado: (2018)

Pooled analysis of the reports of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myeloma
por: Liu, Liping, et al.
Publicado: (2016)

Mechanisms of Action and Clinical Development of Elotuzumab
por: Ritchie, David, et al.
Publicado: (2017)

A case of tumor lysis syndrome and acute renal failure associated with elotuzumab treatment in multiple myeloma
por: Atchison, Douglas K., et al.
Publicado: (2017)

Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns
por: Danhof, Sophia, et al.
Publicado: (2021)

Population pharmacokinetic and exposure–response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma
por: Ide, Takafumi, et al.
Publicado: (2021)

Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin
por: Shimazu, Yutaka, et al.
Publicado: (2023)

Dendritic cell exosomes directly kill tumor cells and activate natural killer cells via TNF superfamily ligands
por: Munich, Stephan, et al.
Publicado: (2012)

Killing the killers
por: De Paepe, Marianne, et al.
Publicado: (2014)

Optimal selection of natural killer cells to kill myeloma: the role of HLA-E and NKG2A
por: Sarkar, Subhashis, et al.
Publicado: (2015)

Interleukin-15 stimulates natural killer cell-mediated killing of both human pancreatic cancer and stellate cells
por: Van Audenaerde, Jonas R.M., et al.
Publicado: (2017)

Elotuzumab for the Treatment of Relapsed or Refractory Multiple Myeloma, with Special Reference to its Modes of Action and SLAMF7 Signaling
por: Taniwaki, Masafumi, et al.
Publicado: (2018)

Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma: ELOQUENT-2 Japanese patient subanalysis
por: Suzuki, K, et al.
Publicado: (2017)

How cells kill a "killer" messenger
por: Saveanu, Cosmin, et al.
Publicado: (2016)

Key Role of the CD56(low)CD16(low) Natural Killer Cell Subset in the Recognition and Killing of Multiple Myeloma Cells
por: Vulpis, Elisabetta, et al.
Publicado: (2018)

Effects of human interleukin-1 on natural killer cell activity: is fever a host defense mechanism for tumor killing?
por: Dinarello, C. A., et al.
Publicado: (1986)

Enavatuzumab, a Humanized Anti-TWEAK Receptor Monoclonal Antibody, Exerts Antitumor Activity through Attracting and Activating Innate Immune Effector Cells
por: Ye, Shiming, et al.
Publicado: (2017)

Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211
por: Usmani, S Z, et al.
Publicado: (2015)

Restoration of NK Cell Cytotoxic Function With Elotuzumab and Daratumumab Promotes Elimination of Circulating Plasma Cells in Patients With SLE
por: Humbel, Morgane, et al.
Publicado: (2021)

Myeloma natural killer cells are exhausted and have impaired regulation of activation
por: D’Souza, Criselle, et al.
Publicado: (2021)

Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study
por: Cella, David, et al.
Publicado: (2018)

Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study
por: Berdeja, Jesus, et al.
Publicado: (2015)

PB2095: ELOTUZUMAB OR DARATUMUMAB IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE (EPD AND DPD) IN RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM): A NETWORK META-ANALYSIS
por: Decimoni, Tassia Cristina, et al.
Publicado: (2023)

Mechanisms of selective killing of neuroblastoma cells by natural killer cells and lymphokine activated killer cells. Potential for residual disease eradication.
por: Foreman, N. K., et al.
Publicado: (1993)

Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials
por: Gentile, Massimo, et al.
Publicado: (2020)

Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial
por: Dimopoulos, Meletios A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lugouq5blsp5e2gvfj7r3002cn